Fostemsavir, a New Option for Multidrug-Resistant HIV-1 Infection

A phase 3 trial shows efficacy of this first-in-class investigational drug.

Although persons with HIV (PWH) that have multidrug-resistant HIV-1 are not as prevalent as before, their treatment options continue to be limited. Investigators now report 48-week results of the ongoing industry-funded phase 3 BRIGHTE trial of fostemsavir, an investigational (not FDA-approved) prodrug that is converted to temsavir, a first-in-class attachment inhibitor that binds to gp120, preventing attachment and entry of the virus into T-cells. The drug inhibits both CCR5- and CXCR4-tropic viruses. Patients with virologic failure and documented resistance to at least four of six antiretroviral classes were assigned to either a randomized or a nonrandomized cohort. Those with at least one but no more than two active drugs available were …

Reviewing Author

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)

Fostemsavir, a New Option for Multidrug-Resistant HIV-1 Infection

Topics

Reviewing Author